Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Does thyroid stunning exist? A model with benign thyroid disease.

O Sabri1, M Zimny, M Schreckenberger

  • 1Clinic of Nuclear Medicine, Aachen University of Technology, Germany.

European Journal of Nuclear Medicine
|December 6, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Capacity for brain amyloid PET in Germany: Results from the 1st survey on nuclear brain imaging in Germany.

European journal of nuclear medicine and molecular imaging·2025
Same author

Prevention of activated brown adipose tissue on <sup>18</sup>F-FDG-PET scans of young lymphoma patients: results of an ancillary study within the EuroNet-PHL-C2 trial.

Scientific reports·2023
Same author

Interplay of tau and functional network connectivity in progressive supranuclear palsy: a [<sup>18</sup>F]PI-2620 PET/MRI study.

European journal of nuclear medicine and molecular imaging·2022
Same author

[Is there an indication for thyroidectomy in cases of minimally invasive follicular thyroid carcinoma?]

Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen·2021
Same author

Use of PET-CT in diagnostic workup of periprosthetic infection of hip and knee joints: significance in detecting additional infectious focus.

International orthopaedics·2021
Same author

Whole-body [<sup>18</sup>F]-FDG-PET/MRI for staging of pediatric non-Hodgkin lymphoma: first results from a single-center evaluation.

EJNMMI research·2021
Same journal

[Not Available].

European journal of nuclear medicine·2016
Same journal

A Window on Latin America.

European journal of nuclear medicine·2016
Same journal

Erratum: Eur J Nucl Med (1999) 26: 686-692.

European journal of nuclear medicine·2016
Same journal

Nuclear medicine in the next decade.

European journal of nuclear medicine·2014
Same journal

Erratum: Impact of attenuation correction on the accuracy of FDG-PET in patients with abdominal tumors: a free-response ROC analysis.

European journal of nuclear medicine·2014
Same journal

(99m)Tc(V)DMSA quantitatively predicts (188)Re(V)DMSA distribution in patients with prostate cancer metastatic to bone.

European journal of nuclear medicine·2014
See all related articles

Thyroid stunning, a reduction in radioiodine uptake, occurs in benign thyroid disease. This phenomenon is directly related to the absorbed radiation dose from the initial radioiodine application, not the activity level.

Area of Science:

  • Nuclear Medicine
  • Endocrinology
  • Radiobiology

Background:

  • Controversy exists regarding radioiodine (131I) diagnostic scans causing "thyroid stunning," reducing subsequent therapeutic 131I uptake in differentiated non-medullary thyroid carcinoma.
  • Quantifying diagnostic 131I absorption (absorbed energy dose) is challenging due to tissue volumetry difficulties, hindering the determination of a stunning threshold.
  • Benign thyroid disease offers quantifiable target volumes via ultrasonography, making it suitable for studying thyroid stunning definitively.

Purpose of the Study:

  • To definitively determine if thyroid stunning occurs in benign thyroid conditions following a second radioiodine application.
  • To investigate the relationship between absorbed energy dose and the extent of thyroid stunning.
  • To identify factors influencing thyroid stunning in patients with benign thyroid disease.

Related Experiment Videos

Main Methods:

  • Studied 171 consecutive patients with benign thyroid disease (diffuse goitre, Graves' disease, toxic nodular goitre) undergoing two-step 131I therapy.
  • Performed kinetic dosimetry for 131I uptake, effective half-life, and absorbed dose for both 131I applications.
  • Utilized ANOVA and multivariate factor analysis to assess factors influencing thyroid stunning.

Main Results:

  • A significant decrease in 131I uptake (31.7%) was observed at the second application, confirming thyroid stunning (P < 0.0005).
  • Effective half-life did not differ significantly between the two applications (P > 0.2).
  • The extent of stunning was significantly influenced only by the absorbed energy dose from the first application (P < 0.0005), not by 131I activity, target volume, gender, or thyroid function.

Conclusions:

  • Thyroid stunning is confirmed to occur in benign thyroid conditions.
  • Thyroid stunning is a radiobiological phenomenon directly correlated with the absorbed energy dose from the initial radioiodine application.
  • The absorbed energy dose, not the initial activity, is the decisive factor influencing thyroid stunning.